Intracameral Use of Nepafenac: Safety and Efficacy Study

References

• Chien D-S. Schoenwald RD: ocular pharmacokinetics and pharmacodynamics of phenylephrine and phenylephrine oxazolidine in rabbit eyes. Pharm Res. 1990;7:476–83. doi:10.1023/A:1015808514727.
   PubMed Web of Science ®Google Scholar
• Fraunfelder FT. Meyer M: possible cardiovascular effects secondary to topical ophthalmic 2.5% phenylephrine. Am J Ophthalmol. 1985;99:362–63. doi:10.1016/0002-9394(85)90371-X.
   PubMed Web of Science ®Google Scholar
• Hakim OJ. Orton RB: topical 2.5% and 5% phenylephrine: comparison of effects on heart rate and blood pressure. Can J Ophthalmol. 1990;25:336–39.
   PubMed Web of Science ®Google Scholar
• Lundberg B, Behndig A. Intracameral mydriatics in phacoemulsification cataract surgery. J Cataract Refract Surg. 2003;29:2366–71. doi:10.1016/S0886-3350(03)00522-4.
   PubMed Web of Science ®Google Scholar
• Cionni RJ, Barros MG, Kaufman AH. Osher RH: cataract surgery without preoperative eye drops. J Cataract Refract Surg. 2003;29:2281–83. doi:10.1016/j.jcrs.2003.09.009.
   PubMed Web of Science ®Google Scholar
• Lundberg B, Behndig A. Intra mydriatics in phacoemulsification surgery obviate the need for epinephrine irrigation. Acta Ophthalmol Scand. 2007;85:546–50. doi:10.1111/j.1755-3768.2007.00892.x.
   PubMedGoogle Scholar
• Osher RH, Ahmed IIK, Demopulos GA. OMS302 (phenylephrine and ketorolac injection) 1%/0.3% to maintain intraoperative pupil size and to prevent postoperative ocular pain in cataract surgery with intraocular lens replacement. Expert Rev Ophthalmol. 2015;10:91–103. doi:10.1586/17469899.2015.1026806.
   Web of Science ®Google Scholar
• Yoon MK, Naseri A, Porco T. McLeod SD: nepafenac-assisted mydriasis in a rabbit model. J Cataract Refract Surg. 2010;36:1779–82. doi:10.1016/j.jcrs.2010.04.033.
   PubMed Web of Science ®Google Scholar
• Atanis R, Tuano PM, Vicencio J, Martinez JM, Verzosa L. Effect of topical ketorolac tromethamine and topical nepafenac in maintaining pupillary dilation during phacoemulsification. Philipp J Ophthalmol. 2011;36:23–27.
   Google Scholar
• Sarkar S, Mondal KK, Roy SS, Gayen S, A G, De RR et al., Comparison of preoperative nepafenac (0.1%) and flurbiprofen (0.03%) eye drops in maintaining mydriasis during small incision cataract surgery in patients with senile cataract: A randomized, double-blind study. Indian J Pharmacol. 2015;47:491–95. doi:10.4103/0253-7613.165201.
   PubMed Web of Science ®Google Scholar
• Koevary SB. Pharmacokinetics of topical ocular drug delivery: potential uses for the treatment of diseases of the posterior segment and beyond. Curr Drug Metab. 2003;4:213–22. doi:10.2174/1389200033489488.
   PubMed Web of Science ®Google Scholar
• Hariprasad SM, Akduman L, Clever JA, Ober M, Recchia FM. Miele WF: treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%. Clin Ophthalmol. 2009;3:147–54. doi:10.2147/OPTH.S4684.
   PubMedGoogle Scholar
• Chastain JE, Sanders ME. Curtis MA: distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye. Exp Eye Res. 2016;145:58e67. doi:10.1016/j.exer.2015.10.009.
   Web of Science ®Google Scholar
• Labetoulle M, Findl O, Malecaze F, Alió J, Cochener B, Lobo C, et al. Evaluation of the efficacy and safety of a standardized intracameral combination of mydriatics and anesthetics for cataract surgery. Br J Ophthalmol. 2016;100:976–85. doi:10.1136/bjophthalmol-2015-307587.
   PubMed Web of Science ®Google Scholar
• Gaynes BI, Fiscella R. Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: a safety review. Drug Saf. 2002;25:233–50. doi:10.2165/00002018-200225040-00002.
   PubMed Web of Science ®Google Scholar
• Gungor SG, Bulam B, Akman A, Colak M. Comparison of intracameral dexamethasone and intracameral triamcinolone acetonide injection at the end of phacoemulsification surgery. Indian J Ophthalmol. 2014;62:861–64. doi:10.4103/0301-4738.141045.
   PubMed Web of Science ®Google Scholar
• Afrashi F, Hashas AS, Shahbazov C, Arici M, Yikilmaz MS, Deveci Ret al., Reliability of intravitreal nepafenac in rabbits. J Ocul Pharmacol Ther. 2015;31:43–50. doi:10.1089/jop.2014.0053.
   PubMed Web of Science ®Google Scholar
• Mamalis N, Edelhauser HF, Dawson DG, Chew J, LeBoyer RM, Werner L et al., Toxic anterior segment syndrome. J Cataract Refract Surg. 2006;32:324–33. doi:10.1016/j.jcrs.2006.01.065.
   PubMed Web of Science ®Google Scholar
• Koban Y, Genc S, Bilgin G, Cagatay HH, Ekinci M, Gecer M et al., Toxic anterior segment syndrome following phacoemulsification secondary to overdose of intracameral gentamicin. Case Rep Med. 2014;2014:143564. doi:10.1155/2014/143564.
   PubMedGoogle Scholar
• Çakır B, Celik E, Aksoy Nö, Bursali Ö, Uçak T, Bozkurt E et al., Toxic anterior segment syndrome after uncomplicated cataract surgery possibly associated with intracameral use of cefuroxime. Clin Ophthalmol. 2015;17:493–97. doi:10.2147/OPTH.S74249.
   Google Scholar
• Gardner S, Barry P, Cordovés L. Toxic anterior segment syndrome and intracameral injection of cefuroxime axetil. Clin Ophthalmol. 2015;9:1865–67. doi:10.2147/OPTH.S91943.
   PubMed Web of Science ®Google Scholar
• Althomali TA. Viscoelastic substance in prefilled syringe as an aetiology of toxic anterior segment syndrome. Cutan Ocul Toxicol. 2016;35:237–41. doi:10.3109/15569527.2015.1082579.
   PubMed Web of Science ®Google Scholar
• Assessment Report Nevanac International non-proprietary name: NEPAFENAC Procedure No. EMEA/H/C/000818/X/0016. The European Medicines Agency (EMEA) Annual Report 2007. 21 February 2013 EMA/393189/2013
   Google Scholar
• Gamache D, Graff G, Brady MT, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation. Inflammation. 2000;24:357–70. doi:10.1023/A:1007049015148.
   PubMed Web of Science ®Google Scholar
• Cervantes-Coste G, Sánchez-Castro YG, Orozco-Carroll M, Mendoza-Schuster E, Velasco-Barona C. Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac. Clin Ophthalmol. 2009;3:219–26. doi:10.2147/OPTH.S4820.
   PubMedGoogle Scholar
• Surhio SA, Memon M, Talpur R. Talpur KI: Efficacy of nepafenac 0.1% in maintaining mydriasis during phacoemulsification surgery. Jlumhs. 2013;12:74–78.
   Google Scholar
• Park SA, Kim NR, Park YW, Jeong MB, Kim WT, Kim SE, et al., Evaluation of the mydriatic effect of intracameral lidocaine hydrochloride injection in the eyes of clinically normal dogs. Am J Vet Res. 2009;70:1521–25. doi:10.2460/ajvr.70.12.1521.
   PubMed Web of Science ®Google Scholar
• Park SA, Park YW, Son WG, Kim TH, Ahn JS, Ahn JT et al., Evaluation of the analgesic effect of intracameral lidocaine hydrochloride injection on intraoperative and postoperative pain in healthy dogs undergoing phacoemulsification. Am J Vet Res. 2010;71:216–22. doi:10.2460/ajvr.71.2.216.
   PubMed Web of Science ®Google Scholar
• Nikeghbali A, Falavarjani KG, Kheirkhah A, Bakhtiari P, Kashkouli MB. Pupil dilation with intracameral lidocaine during phacoemulsification. J Cataract Refract Surg. 2007;33:101–03. doi:10.1016/j.jcrs.2006.08.044.
   PubMed Web of Science ®Google Scholar
• Nikeghbali A, Falavarjani KG, Kheirkhah A. Pupil dilation with intracameral lidocaine during phacoemulsification: Benefits for the patient and surgeon. Indian J Ophthalmol. 2008;56:63–64. doi:10.4103/0301-4738.37598.
   PubMed Web of Science ®Google Scholar